arrow_back Back to App

Supporting Fungal Disease Research and Drug Development

This act aims to accelerate research and development of new drugs, vaccines, and diagnostics for fungal diseases, such as Valley Fever. Citizens can expect improved health protection through faster access to more effective treatments and prevention methods for these conditions. Increased funding and inter-agency cooperation are intended to enhance the fight against drug-resistant infections.
Key points
Increased funding for research into endemic fungal diseases, including Valley Fever, potentially leading to new discoveries and therapies.
Establishment of an expert working group to coordinate efforts and identify gaps in fungal disease research.
Expedited approval process for new Valley Fever drugs and vaccines by the Food and Drug Administration (FDA).
Creation of a program to support the development of products combating antimicrobial resistance, with a focus on antifungal therapies.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3498
Sponsor: Sen. Kelly, Mark [D-AZ]
Process start date: 2022-01-13
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

FORWARD Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3498.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-01-13.

What are the main provisions?

Key points include:

  • Increased funding for research into endemic fungal diseases, including Valley Fever, potentially leading to new discoveries and therapies.
  • Establishment of an expert working group to coordinate efforts and identify gaps in fungal disease research.
  • Expedited approval process for new Valley Fever drugs and vaccines by the Food and Drug Administration (FDA).
  • Creation of a program to support the development of products combating antimicrobial resistance, with a focus on antifungal therapies.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Kelly, Mark [D-AZ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health